Upgrades HUTCHMED (NASDAQ:HCM) to “Buy” upgraded shares of HUTCHMED (NASDAQ:HCMFree Report) from a hold rating to a buy rating in a report published on Monday morning.

HUTCHMED Trading Up 4.0 %

Shares of HUTCHMED stock opened at $18.64 on Monday. The company’s fifty day simple moving average is $18.73 and its 200-day simple moving average is $17.02. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.60 and a current ratio of 2.72. HUTCHMED has a 1 year low of $10.68 and a 1 year high of $21.92.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of HCM. Vanguard Personalized Indexing Management LLC bought a new position in shares of HUTCHMED during the third quarter valued at $196,000. Hsbc Holdings PLC acquired a new stake in HUTCHMED in the third quarter worth about $380,000. Acadian Asset Management LLC acquired a new stake in HUTCHMED in the third quarter worth about $3,268,000. Connor Clark & Lunn Investment Management Ltd. bought a new stake in shares of HUTCHMED in the 3rd quarter valued at about $444,000. Finally, China Universal Asset Management Co. Ltd. increased its stake in shares of HUTCHMED by 353.7% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 3,593 shares of the company’s stock valued at $65,000 after acquiring an additional 2,801 shares during the last quarter. 8.82% of the stock is owned by institutional investors.

HUTCHMED Company Profile

(Get Free Report)

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors.

Further Reading

Receive News & Ratings for HUTCHMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HUTCHMED and related companies with's FREE daily email newsletter.